Correlation between loss of Bcl-XL expression and improved prognosis in advanced esophageal cancer treated by preoperative chemoradiotherapy

European Surgical Research

Volumn 41, Issue 3, 2008, Pages 260-266

  Okumura, M ^a,b   Kajiyama, Y ^a   Takeda, K ^a   Okumura, K ^a   Tsurumaru, M ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Advanced esophageal cancer; Apoptosis; Bcl 2; Bcl XL; FADD; Preoperative chemoradiotherapy; Survival time

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; FAS ASSOCIATED DEATH DOMAIN PROTEIN; PROTEIN BCL XL; PROTEIN BNIP3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOPSY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOTHERAPY; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BCL-X PROTEIN; CASPASE 3; CASPASE 8; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DNA PRIMERS; ESOPHAGEAL NEOPLASMS; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; GENE EXPRESSION; GENES, BCL-2; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; RADIATION-SENSITIZING AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TAXOIDS;

EID: 53849102946     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141515     Document Type: Article

References (22)

1. Collard JM, Otte JB, Fiasse R, Laterre PF, De Kock M, Longueville J, Glineur D, Romagnoli R, Reynaert M, Kestens PJ: Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001;234:25-32.
2. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225-232.
3. Ando N, Iizuka T, Kakegawa T, Isono K, Watanabe H, Ide H: A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114:205-209.
4. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP, Launois B: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of esophagus. Cancer 1994;73:1779-1784.
5. Wallach D, Varfolomeev EE, Nalinin NL, Goltsev YV, Kovalenko AV, Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-367.
6. Nagata S, Golstein P: The Fas death factor. Science 1995;267:1449-1456.
7. Earnshaw WC, Martins LM, Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
8. Wolf BB, Green DR: Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 1998;274:20049-20052.
9. Zheng TS, Flavell RA: Divinations and surprises: genetic analysis of caspase function in mice. Exp Cell Res 2000;256:67-73.
10. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998;281:1305-1308.
11. Chnnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
12. Varadhachary AS, Edidin M, Hanlon AM, Peter ME, Krammer PH, Salgame P: Phosphatidylinositol 3′-kinase blocks CD95 aggregation and caspase-8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD95. J immunol 2001;166:6564-6569.
13. Krammer PH: CD95's deadly mission in the immune system. Nature 2000;407:789-795.
14. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
15. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
16. Yang X, Zheng F, Xing H, Gao Q, Wei W, Lu Y, Wang S, Zhou J, Hu W, Ma D: Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 2004;130:423-428.
17. Puglisi F, Loreto C Di, Panizzo R, Avellini C, Fougione S, Cacitti V, Belttrami CA: Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the esophagus. J Clin Pathol 1996;49:456-459.
18. Geh JI, Crellin AM, Glynne-Jones: Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001;88:338-356.
19. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003;349:2241-2252.
20. L are not related to prognosis in patients with advanced esophageal squamous cell carcinoma. Cancer Lett 2001;174:91-97.
21. Ashkenazi A: Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-430.
22. Lake RA, Robinson BWS: Immunotherapy and chemotherapy - a practical partner. Nat Rev Cancer 2005;5:397-405.